Literature DB >> 18381647

Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.

Javier Pagonabarraga1, Jaime Kulisevsky1, Gisela Llebaria1, Carmen García-Sánchez1, Berta Pascual-Sedano1, Alexandre Gironell1.   

Abstract

Cognitive defects associated with cortical pathology may be a marker of dementia in Parkinson's disease (PD). There is a need to improve the diagnostic criteria of PD dementia (PDD) and to clarify the cognitive impairment patterns associated with PD. Current neuropsychological batteries designed for PD are focused on fronto-subcortical deficits but are not sensitive for cortical dysfunction. We developed a new scale, the Parkinson's Disease-Cognitive Rating Scale (PD-CRS), that was designed to cover the full spectrum of cognitive defects associated with PD. We prospectively studied 92 PD patients [30 cognitively intact (CogInt), 30 mild cognitive impairment (MCI), 32 PDD] and 61 matched controls who completed the PD-CRS and neuropsychological tests assessing the cognitive domains included in the PD-CRS. Acceptability, construct validity, reliability, and the discriminative properties of the PD-CRS were examined. The PD-CRS included items assessing fronto-subcortical defects and items assessing cortical dysfunction. Construct validity, test-retest and inter-rater reliability of PD-CRS total scores showed an intraclass correlation coefficient >0.70. The PD-CRS showed an excellent test accuracy to diagnose PDD (sensitivity 94%, specificity 94%). The PD-CRS total scores and confrontation naming item scores-assessing "cortical" dysfunction-independently differentiated PDD from non-demented PD. Alternating verbal fluency and delayed verbal memory independently differentiated the MCI group from both controls and CogInt. The PD-CRS appeared to be a reliable and valid PD-specific battery that accurately diagnosed PDD and detected subtle fronto-subcortical deficits. Performance on the PD-CRS showed that PDD is characterized by the addition of cortical dysfunction upon a predominant and progressive fronto-subcortical impairment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381647     DOI: 10.1002/mds.22007

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  88 in total

Review 1.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

Review 2.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

Review 3.  Parkinson's disease dementia.

Authors:  Mary J Docherty; David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 4.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

5.  Clinical differences among mild cognitive impairment subtypes in Parkinson's disease.

Authors:  Jennifer G Goldman; Holly Weis; Glenn Stebbins; Bryan Bernard; Christopher G Goetz
Journal:  Mov Disord       Date:  2012-07-06       Impact factor: 10.338

Review 6.  Mild cognitive impairment in Parkinson's disease.

Authors:  Saul Martinez-Horta; Jaime Kulisevsky
Journal:  J Neural Transm (Vienna)       Date:  2019-04-08       Impact factor: 3.575

7.  A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment.

Authors:  Ignacio Aracil-Bolaños; Frederic Sampedro; Juan Marín-Lahoz; Andrea Horta-Barba; Saül Martínez-Horta; Mariángeles Botí; Jesús Pérez-Pérez; Helena Bejr-Kasem; Berta Pascual-Sedano; Antonia Campolongo; Cristina Izquierdo; Alexandre Gironell; Beatriz Gómez-Ansón; Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Hum Brain Mapp       Date:  2019-04-01       Impact factor: 5.038

8.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

9.  Standardization and normative data obtained in the Italian population for a new verbal fluency instrument, the phonemic/semantic alternate fluency test.

Authors:  Alberto Costa; Eriola Bagoj; Marco Monaco; Silvia Zabberoni; Salvatore De Rosa; Anna Maria Papantonio; Ciro Mundi; Carlo Caltagirone; Giovanni Augusto Carlesimo
Journal:  Neurol Sci       Date:  2013-08-21       Impact factor: 3.307

10.  Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease.

Authors:  Jennifer G Goldman; Samantha Holden; Bryan Bernard; Bichun Ouyang; Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2013-10-09       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.